{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:15:42Z","timestamp":1783574142116,"version":"3.55.0"},"reference-count":5,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Isatuximab, an anti-CD38 monoclonal antibody, is a cornerstone therapy for multiple myeloma (MM). Standard intravenous infusion requires a minimum of 75 minutes per dose, representing a significant burden on patients and day-hospital resources. A rapid 30-minute infusion protocol has shown promise in early clinical trials, but large real-world datasets remain scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a descriptive, retrospective, multicenter study across 9 Spanish hospitals, including patients with confirmed MM who had received at least one rapid (30-minute) intravenous isatuximab infusion. Demographic, clinical, treatment, and safety data were collected. Infusion-related reactions (IRRs) were graded per CTCAE v5.0. Data cut-off: 1 May 2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 103 patients were included (median age 66 years; 54.4% female). A total of 1,344 rapid 30-minute infusions were administered. Only 1 IRR was recorded: per-patient rate 0.97% (95% CI: 0.17%\u20135.30%), per-infusion rate 0.074% (95% CI: 0.013%\u20130.420%). Notably, 22 patients (21.4%) had experienced IRRs at standard rate; 21 of these (95.5%) completed the rapid protocol without reverting to standard rate. No patient permanently discontinued isatuximab due to an IRR. No treatment failure was attributable to the infusion rate change during the observation period. The protocol generated an estimated 1,008 hours of cumulative day-hospital chair time savings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Rapid 30-minute intravenous isatuximab demonstrates an excellent real-world safety profile, including in patients with prior IRRs, and generates clinically meaningful resource savings. To our knowledge, this is the largest published real-world cohort to date. These findings support its use as a feasible implementation strategy while prospective comparative studies remain warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1906850","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:19:28Z","timestamp":1783570768000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world safety of rapid 30-minute intravenous isatuximab infusion in multiple myeloma: results from the largest published cohort"],"prefix":"10.3389","volume":"16","author":[{"given":"Xabier","family":"Guti\u00e9rrez L\u00f3pez De Oc\u00e1riz","sequence":"first","affiliation":[{"name":"Servicio de Hematologia (Hematology Department), Araba University Hospital","place":["Vitoria-Gasteiz, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"P\u00e9rez Persona","sequence":"additional","affiliation":[{"name":"Servicio de Hematologia (Hematology Department), Hospital Universitario de Navarra","place":["Pamplona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Salcedo Cuesta","sequence":"additional","affiliation":[{"name":"Servicio de Hematologia (Hematology Department), Araba University Hospital","place":["Vitoria-Gasteiz, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eusebio","family":"Mart\u00edn Chac\u00f3n","sequence":"additional","affiliation":[{"name":"Servicio de Hematologia (Hematology Department), Hospital Universitario Virgen del Rocio","place":["Seville, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maialen","family":"Sirvent Auzmendi","sequence":"additional","affiliation":[{"name":"Servicio de Hematologia (Hematology Department), Hospital Universitario de Donostia","place":["Donostia-San Sebastian, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Millacoy Austerrritt","sequence":"additional","affiliation":[{"name":"Servicio de Hematologia (Hematology Department), Hospital Universitario de Donostia","place":["Donostia-San Sebastian, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Lorenzo P\u00e9rez","sequence":"additional","affiliation":[{"name":"Servicio de Hematologia (Hematology Department), Hospital Alvaro Cunqueiro","place":["Vigo, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Landete Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Servicio de Hematologia (Hematology Department), Hospital Universitario Infanta Leonor","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Carrasco Baraja","sequence":"additional","affiliation":[{"name":"Servicio de Hematologia (Hematology Department), Hospital Royo Villanova","place":["Zaragoza, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Sanch\u00e9z Romero","sequence":"additional","affiliation":[{"name":"Servicio de Hematologia (Hematology Department), Hospital Universitario de Valme","place":["Seville, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Ivett Ar\u00e1mbula","sequence":"additional","affiliation":[{"name":"Servicio de Hematologia (Hematology Department), Hospital Universitario de Valme","place":["Seville, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ianire","family":"Etxeguren Urkixo","sequence":"additional","affiliation":[{"name":"Servicio de Hematologia (Hematology Department), Hospital de Galdakao-Usansolo","place":["Galdakao, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"B1","unstructured":"Sarclisa (Isatuximab) [Prescribing Information]\n          \n          2024"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70041","article-title":"30-minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: results of a phase 1b study analysis","volume":"8","author":"Ocio","year":"2024","journal-title":"HemaSphere"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.01.022","article-title":"Real-world safety and tolerability of rapid, 30-minutes, intravenous isatuximab in patients with multiple myeloma","volume":"25","author":"Kotb","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00744","article-title":"Isatuximab subcutaneous by on-body injector versus isatuximab intravenous plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma: phase III IRAKLIA study","volume":"43","author":"Ailawadhi","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1906850\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:19:30Z","timestamp":1783570770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1906850\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":5,"alternative-id":["10.3389\/fonc.2026.1906850"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1906850","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"article-number":"1906850"}}